Showing 1321-1330 of 2874 results for "".
- First Participant Enrolled in Phase 3 Study of Vidofludimus Calcium for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/first-participant-enrolled-in-phase-3-study-of-vidofludimus-calcium-for-relapsing-multiple-sclerosis/2469761/The first participant has enrolled in the phase 3 ENSURE-1 clinical trial (NCT05134441) of vidofludimus calcium (IMU-838; Immunic Therapeutics, New York, NY) for potential treatment of relapsing m
- Nilvadipine Slowed Cognitive Decline in Early- but not Late-Stage Alzheimer Disease in Clinical Trial Post Hoc Analysishttps://practicalneurology.com/news/nilvadipine-slowed-cognitive-decline-in-early-but-not-late-stage-alzheimer-disease-in-clinical-trial-post-hoc-analysis/2469182/New data from a clinical NILVAD trial (NCT02017340) of nilvadipine (Alzforum, Archer Pharmaceuticals, Sarasota, FL) Alzheimer disease (AD) using nilvadipine identified that individuals with very m
- Vazegepant Relieves Pain And Most Bothersome Symptoms in Phase 2/3 Trialhttps://practicalneurology.com/news/vazegepant-relieves-pain-and-most-bothersome-symptoms-in-phase-23-trial/2469112/In a pivotal phase 2/3 clinical trial (NCT03872453), vazegepant (Biohaven Pharmaceutical, New Haven, CT). Participants in the trial (n=1,673) were randomly assigned to receive 5 mg, 10 mg, or 20 m
- Cenobamate Reduces Seizure Frequency Significantly in Phase 2 Trialhttps://practicalneurology.com/news/cenobamate-reduces-seizure-frequency-significantly-in-phase-3-trial/2469075/In the phase 2 trial (NCT01866111) treatment with cenobamate (SK Life Science, Paramus, NJ) resulted in statistically significant greater reductions in focal seizure frequency compared with baseline. Those treated with cenobamate 100 m
- Vamorolone Has Efficacy for Treating Duchenne Muscular Dystrophy Without Affecting Growthhttps://practicalneurology.com/news/vamorolone-has-efficacy-for-treating-duchenne-muscular-dystrophy-without-affecting-growth/2470013/In the VISION-DMD trial (NCT02760277), children with Duchenne muscular dystrophy (DMD) treated with vamorolone (ReveraGen BioPharma, Rockville, MD), had improved motor function with no negative effects on linear growth or biomarkers of
- Sargramostim Improves Motor Symptoms of Parkinson Disease in Small Phase 1 Trialhttps://practicalneurology.com/news/sargramostim-improves-motor-symptoms-of-parkinson-disease-in-small-phase-1-trial/2469597/An investigator-initiated clinical trial (NCT03790670) evaluated the use of sargramostim (Leukine; Partner Therapeutics, Lexington, MA). Improvements in MDS-UPDRS Part 3 scores, which measure motor sympto
- Validation of an Algorithmic EEG-Based Diagnostic Tool for Concussionhttps://practicalneurology.com/news/validation-of-an-algorithmic-eeg-based-diagnostic-tool-for-concussion/2469505/A study validating an EEG-based algorithmic concussion assessment tool (Concussion Index; Brainscope, Bethesda, MD) has been published in JAMA Open Network for evaluating severity of concussion
- Cannabidiol Reduces Seizures in People With Tuberous Sclerosis Complex-Related Seizures in Clinical Trialshttps://practicalneurology.com/news/cannabidiol-reduces-seizures-in-people-with-tuberous-sclerosis-complex-related-seizures-in-clinical-trials/2469097/Findings from a clinical trial (NCT02544763) presented at the American Epilepsy Society Annual Meeting December 6-10, 2019 in Baltimore, MD showed that people with tuberous sclerosis complex (TSC), a genetic condition associated with t
- Positive Phase 2 Results for Evobrutinib Treatment of MS and Initiation of Phase 3 Trialshttps://practicalneurology.com/news/positive-phase-2-results-for-evobrutinib-treatment-of-ms-and-initiation-of-phase-3-trials/2469014/At the European Committee on Research and Treatment in Multiple Sclerosis (ECTRIMS) Congress in Stockholm, Sweden September 11-13, 2019, data from a phase 2 trial (NCT02975349) of evobrutinib (EMD Serono, Rockland, MD) for treatment of
- Eye Tracking Technology Detects Traumatic Brain Injury With Sensitivity and Specificityhttps://practicalneurology.com/news/eye-tracking-technology-detects-traumatic-brain-injury-with-sensitivity-and-specificity/2469003/Research findings published in Concussion show that measurement of horizontal saccades with eye-tracking technology (Brain Health EyeQ; RightEye, Bethesda, MD) has a 77% sensitivity and 78% specificity for i